NuVasive Shares Popped: What You Need to Know (NUVA)

NuVasive Shares Popped: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of NuVasive (Nasdaq: NUVA ) , a medical device company that specializes in treatments of the spine, rocketed higher by as much as 25% today following an upgrade by Canaccord Genuity earlier in the week.

So what: It's been a delayed reaction, but Canaccord life sciences analyst William Plovanic referred to NuVasive as the "best asset in its class." He noted that there have been products which haven't performed as well as once anticipated and that legal issues still exist for the company. In fact, a hearing is scheduled for tomorrow whereby Medtronic (NYSE: MDT ) will be seeking an injunction against NuVasive for allegedly infringing on some of its patents. Taking all of this into account, Mr. Plovanic placed a $19 price target on the company.

Now what: This is as good a time as any to be reminded that analyst upgrades and downgrades are largely one-day to one-week events and don't have much bearing on the long-term outlook of a stock. NuVasive is in one of my favorite fields -- medical devices -- and its sales are increasing nicely. Unfortunately, Wall Street estimates show that legal woes and the lag time related to introducing new products is going to stymie EPS growth for at least the next year or two. Following today's huge rally, I'm more than content to pass on NuVasive here and perhaps re-evaluate it on a dip.

Craving more input? Start by adding NuVasive to your free and personalized watchlist so you can keep up with the latest news from the company.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.